ArticleBMC cancer2026
Prognostic significance of the pan-immune-inflammatory value (PIV) in gastric cancer: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- A novel inflammation and tumor marker-based prognostic score, neutrophil-lymphocyte ratio-C-reactive protein-Ca19-9, in metastatic gastric cancer.Oncology letters · 2026Article
- Pan-Immune-Inflammation Value as a Novel Predictor of Contrast-Associated Acute Kidney Injury in Patients Treated with Primary PCI for STEMI.Journal of clinical medicine · 2026Article
- Pan-immune-inflammation value is a novel prognostic biomarker in pT2-4 gastric cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesPeripheral blood cell parameters are used as prognostic markers in gastric cancer. In this study, we evaluated the prognostic significance of the Pan-Immune-Inflammatory Value (PIV), calculated as (neutrophil × platelet × monocyte) / lymphocyte counts, in patients with gastric cancer.
methodsThe study included 120 patients with gastric adenocarcinoma who were followed at the Department of Medical Oncology, Sultan Abdulhamid Han Training and Research Hospital, University of Health Sciences, between September 2017 and December 2024. PIV was calculated from pre-treatment complete blood counts. Associations between PIV and overall survival (OS), progression-free survival (PFS), and treatment response were analyzed. In our study, receiver operating characteristic (ROC) analysis was performed to determine the optimal cut-off value for PIV to achieve prognostic discrimination. Survival analyses were performed using the Kaplan-Meier method, and differences between groups were compared with the log-rank test. Univariate and multivariate Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression analysis was performed to identify independent predictors of treatment response.
resultsThe optimal cut-off value for PIV was 334.8, and 49.2% of patients had a PIV above this value. Patients with a high PIV (≥ 334.8) had significantly poorer PFS (HR = 1.975; 95% CI: 1.046-3.730; p = 0.036) and OS (HR = 2.286; 95% CI: 1.332-3.924; p = 0.003) compared with those in the low PIV group. A significant association was observed between PIV and treatment response. Patients with low PIV had significantly higher response rates than those with high PIV.
conclusionsOur study suggests that PIV can be considered a prognostic parameter for overall survival in patients with gastric adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.